BARCELONA, Spain, June 1 /PRNewswire/ – Organizations are moving to Veeva Vault EDC for increased speed and efficiency
Veeva Systems (NYSE: VEEV) today announced the increasing adoption of Veeva Vault EDC as leading companies – including 6 of the top 20 pharmaceutical companies – seek to modernize the way they manage clinical data. With Vault EDC’s advanced data capabilities to streamline study design and data processing, organizations can achieve significant time, labor and cost savings and deliver a better research site experience.
As study complexity increases, biopharmaceutical companies require agile systems that enable clinical teams to quickly design, launch, conduct and modify all types of studies. Vault EDC provides dynamic design tools that automate manual processes and enable faster study design. Over the course of the study, Vault EDC users can make changes without expensive data migrations.
“The industry is making significant strides in its transition to patient-centric trials,” said Richard Young, vice president, Vault CDMS at Veeva. “We are committed to providing data managers with the innovation they need to balance complex scientific endeavors with operational excellence in that will advance clinical data management. We thank our customers, particularly our early adopters, for the close collaboration over the past few years as we have evolved our product offering.”
Vault EDC is part of the Veeva Vault clinical suite and integrates with Veeva Vault CTMS to provide seamless data flow for efficient operations and a superior user interface and workflow for CRAs and other clinical professionals.
What the industry is saying about Veeva Vault EDC
“With the innovative capabilities of Veeva Vault EDC, we have reduced the time it takes to create studies by 30-35% compared to pre-2021,” said Mayank Anand, vice president and global head of data strategy and management at GSK. “Veeva is an important part of our data strategy for the future.”
“As we work with different CROs, Veeva Vault EDC ensures consistency in our data and speeds the creation and modification of studies,” said Evelyn Dorsey, Director of Data Management at Cara Therapeutics. “We are now able to provide flexible reports Leverage to share custom metrics and provide easy access for CRO team members, simplifying collaboration and increasing overall efficiency.”
“We are excited to expand our partnership and include Veeva Vault EDC as part of our standard operating model,” said Mark Morais, COO at Labcorp Drug Development. “Veeva EDC has helped us modernize our data operations, create studies faster and change and ultimately provide study data more effectively.”
“We are focused on running a global adaptive platform for PHASE I, II and III trials with large patient populations and needed an electronic data collection system that could keep pace with the dynamic nature of our trials,” said Michael Lambert, Vice President, Data Management at Platform Life Sciences, “Veeva Vault EDC allows us to make changes to our data pipeline or protocol to gain faster insights. This allows us to quickly respond to changes in CRF or ICF and drive studies forward.”
For more information on Veeva Vault EDC, visit: veeva.com/eu/EDC
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the world’s leading provider of cloud software for the life sciences industry. Committed to innovation, product quality and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotech companies. As a not-for-profit company, Veeva strives to balance the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. Visit veeva.com/eu for more information.
Veeva: Forward-Looking Statements
This press release contains forward-looking statements about Veeva’s products and services and the anticipated results or benefits of using our products and services. These statements are based on our current expectations. Actual results could differ materially from those set forth in this press release, and we undertake no obligation to update such statements. There are numerous risks that could potentially adversely affect our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2022, which can be found here (a summary of For risks that may affect our business, see pages 39 and 40) and our subsequent SEC filings, which can be accessed at sec.gov.
Jeremy Whittaker Deivis Mercado
Veeva Systems Veeva Systems
+49-695-095-5486 firstname.lastname@example.org 925-226-8821 email@example.com
View original content: